title stringlengths 1 1.19k | keywords stringlengths 0 668 | concept stringlengths 0 909 | paragraph stringlengths 0 61.8k | PMID stringlengths 10 11 |
|---|---|---|---|---|
Strategies to improve adherence to interventions {11c} | Using a commercially available feedback device ( | PMC10413586 | ||
Relevant concomitant care permitted or prohibited during the trial {11d} | During the trial, NHSBT standard care has been in place to ensure donor safety. This includes a screening procedure to ensure the donor is healthy and any medication does not impact donor health or the donation process (including study interventions). As noted above, if a donor has declined to receive the trial interve... | PMC10413586 | ||
Provisions for post-trial care {30} | Given its interventions, this trial is considered minimal risk; no specific post-trial care has, therefore, been provided. | PMC10413586 | ||
Outcomes {12} | PMC10413586 | |||
Primary outcome | loss of consciousness | COMPLICATIONS | The primary outcome is the number of in-session VVRs with loss of consciousness (i.e. episodes involving loss of consciousness of any duration, with or without additional complications). | PMC10413586 |
Secondary outcomes | bruising, loss of consciousness, rebleeds, non-VVR adverse | ADVERSE EVENTS, EVENT, APPENDIX, SECONDARY | Secondary outcomes are (i) all in-session VVRs (i.e. with and without loss of consciousness); (ii) all delayed VVRs (i.e. VVRs with and without loss of consciousness after leaving the donation venue); (iii) delayed VVRs with loss of consciousness; and (iv) any in-session non-VVR adverse events or reactions, such as bru... | PMC10413586 |
Participant timeline {13} | All donors who have attended a blood donation session from 4 | PMC10413586 | ||
Sample size {14} | syncope | The trial sample size has been informed by (i) the need to generate evidence sufficiently compelling to influence regulators and policy-makers; (ii) NHSBT's duty of care to 900,000 blood donors per year, making it vital for the service to evaluate even small changes in VVR rates; (iii) NHSBT’s objective to optimise blo... | PMC10413586 | |
Recruitment {15} | All individuals who have donated blood in one of NHSBT’s blood donation sessions during the trial period have been included in the trial, unless they opted out using the procedure described above. | PMC10413586 | ||
Assignment of interventions: allocation | PMC10413586 | |||
Sequence generation {16a} | Randomisation of donation sites (“clusters”) to intervention sequences has been undertaken at the trial’s academic coordinating centre, using a computer program written to implement a previously described method for sequential treatment assignment, balancing for known prognostic factors [ | PMC10413586 | ||
Concealment mechanism {16b} | During the study period, only two people (the trial statistician and study coordinator) were aware of the study randomisation. NHSBT teams (clusters) were informed of the upcoming intervention changes approximately 1 week prior to commencement to allow them to order supplies to deliver the interventions. This process w... | PMC10413586 | ||
Implementation {16c} | The trial statistician at the academic coordinating centre generated the allocation sequence at the beginning of the trial. Every 9 months, when the intervention allocations changed, the trial statistician contacted staff at NHSBT to roll out the next phase of interventions. | PMC10413586 | ||
Assignment of interventions: blinding | PMC10413586 | |||
Who will be blinded {17a} | As noted above, participants and analysts have not been blinded to the interventions they have received. | PMC10413586 | ||
Procedure for unblinding if needed {17b} | Not applicable, this trial is not blinded. | PMC10413586 | ||
Data collection and management | PMC10413586 | |||
Plans for assessment and collection of outcomes {18a} | SFTP | ADVERSE EVENTS, EVENTS | Via a Secure File Transfer Protocol (SFTP), NHSBT staff have shared pseudonymised information about donors’ demographic characteristics and adverse donation events (including VVRs) with authorised staff at the academic coordinating centre. All data shared have been strictly pseudonymised (i.e. stripped of personal iden... | PMC10413586 |
Plans to promote participant retention and complete follow-up {18b} | Not applicable; this trial does not involve the need for participant retention or follow-up beyond the mechanisms described above. | PMC10413586 | ||
Data management {19} | SFTP | ADVERSE EVENTS | A formal Data Sharing Agreement was agreed between NHSBT and the University of Cambridge, prior to the start of the STRIDES trial. On a daily basis, NHSBT staff have forwarded to an authorised data manager at the academic coordinating centre pseudonymised extracts from NHSBT’s database including information on donors: ... | PMC10413586 |
Plans to give access to the full protocol, participant-level data and statistical code {31c} | Data access requests should be made to donorhealth@medschl.cam.ac.uk. | PMC10413586 | ||
Confidentiality {27} | Not applicable; no personal, identifiable information is collected as part of this trial. | PMC10413586 | ||
Plans for collection, laboratory evaluation and storage of biological specimens for genetic or molecular analysis in this trial/future use {33} | SECONDARY | During the trial period, a subset of donors have been asked if they wish to join the STRIDES/NIHR BioResource – Research Tissue Bank (henceforth, ‘STRIDES BioResource’), in keeping with the trial’s secondary objective to advance understanding of the determinants of VVRs and to help develop prevention strategies for VVR... | PMC10413586 | |
Statistical methods | PMC10413586 | |||
Statistical methods for primary and secondary outcomes {20a} | PMC10413586 | |||
Principles | Intention-to-treat analyses will be used. Principal analyses will concern the assessment of the main effects of interventions based on outcomes aggregated at the site level (i.e. unit of randomisation). Tests of interaction will assess whether results differ between pre-specified subgroups. Subsidiary analyses will be ... | PMC10413586 | ||
End-of-trial analyses | SECONDARY | Primary analyses will calculate odds ratios for the main effects of interventions using a binomial generalised linear mixed model fitted to the aggregate number of primary outcomes recorded in each 9-month period by site with the denominator as the number of donations recorded by site-period (defined by NHSBT as a comp... | PMC10413586 | |
Interim analyses {21b} | Not applicable; interim analyses have not taken place as the trial has been judged to be minimal risk. | PMC10413586 | ||
Methods for additional analyses (e.g. subgroup analyses) {20b} | Key additional analyses will include an assessment of interactions of interventions and possible variation of the intervention main effects by period and site-level baseline characteristics, including faint rates (tertiles); size as characterised by a number of donors bled (tertiles); and type of site (fixed or mobile)... | PMC10413586 | ||
Methods in analysis to handle protocol non-adherence and any statistical methods to handle missing data {20c} | As noted above, all analyses will involve the intention to treat principle. Data on outcomes and covariates are expected to be mostly complete as they are anonymously collected from routine blood donation records, with low opt-out rates for use in consented research. We will report on any missing data, but will not con... | PMC10413586 | ||
Oversight and monitoring | PMC10413586 | |||
Composition of the coordinating centre and trial steering committee {5d} | The Trial Steering Committee monitors the overall conduct of the trial and, through its independent Chair, provides strategic advice to the Trial Management Group. The Trial Steering Committee includes several senior clinical and academic members who are independent from the trial investigators, two lay representatives... | PMC10413586 | ||
Composition of the data monitoring committee, its role and reporting structure {21a} | RECRUITMENT | An independent data monitoring committee was not set up for this study. The main reason for this is the study is minimal risk to human health. The Trial statistician has analysed information on recruitment, baseline characteristics, and total counts of all VVRs recorded approximately two times per year, and presented s... | PMC10413586 | |
Patient and public involvement and engagement | Within the department, there is a well-established panel of public contributors who are current or past blood donors. Two members of the public (blood donors) joined the STRIDES trial management group (TMG) during the design phase and a third member of the public joined six months before the start of the feasibility st... | PMC10413586 | ||
Adverse event reporting and harms {22} | ADVERSE EVENTS, ADVERSE EVENT | Any serious adverse events that occurred during or immediately after the study period will be reported to the Research Ethics Committee and NHSBT by email (cambridgesouth.rec@hra.nhs.uk) within 24 h days, according to the Health Research Authority guidelines. Adverse events that are not serious are recorded and the spo... | PMC10413586 | |
Frequency and plans for auditing trial conduct {23} | As noted above, during the trial period, each blood donation team within NHSBT has been audited at least once during each intervention period (i.e. every 9 months). During these visits, NHSBT staff members recorded what interventions were in place at the team they visit along with any other relevant observations. The s... | PMC10413586 | ||
Plans for communicating important protocol amendments to relevant parties (e.g. trial participants, ethical committees) {25} | Study amendments, following approval from the Research Ethics Committee and the Sponsor, have been communicated to NHSBT blood donation teams via email. If additional training has been needed, virtual training sessions have been set up to ensure the amendment has been understood and implemented. | PMC10413586 | ||
Dissemination plans {31a} | Results from this study will directly inform NHSBT’s blood donation policies. The results will also be published in relevant journals and presented at conferences across the world. Our PPIE members will also be involved in the dissemination of results through our Trial Steering Committee and TMG. | PMC10413586 | ||
Discussion | To our knowledge, STRIDES is the largest and most comprehensive cluster randomised trial to date in the prevention of VVR among whole blood donors. The rationale for its conduct was suggested by our prior systematic review and meta-analysis of previous randomised trials assessing the effects of water loading, AMT and o... | PMC10413586 | ||
Trial status | RECRUITMENT | Recruitment to the STRIDES study began in November 2019 and will complete in November 2022. Currently protocol version v4.0, 13.07.2020 | PMC10413586 | |
Acknowledgements | Turner and Laura Wood, Hunt/Lydia, Alison Dent / Claudia, Sutton Coldfield | SLOUGH, WRIGHT, STUART, BRAIN, DAWSON, WELLS, ROBINSON, HEART, GROVER, GILCHRIST | This work was supported by Health Data Research UK, which is funded by the UK Medical Research Council, Engineering and Physical Sciences Research Council, Economic and Social Research Council, Department of Health and Social Care
(England), Chief Scientist Office of the Scottish Government Health and Social Care Direc... | PMC10413586 |
Authors’ contributions {31b} | SD | EDA and JD are the chief investigators. AM, SK, MW, PTG, NW, NK, NA, JRB, GM and DJR are co-investigators. SK is the chief statistician. MS, AMW and RC are trial statisticians. MW is the chief data manager. SM, DC, RG and LA led the study within NHSBT. JS and KS managed the samples collected. SF managed the PPIE input ... | PMC10413586 | |
Funding {4} | ’ S.K. | BLOOD, HEART | The trial is funded by NHS Blood and Transplant and the NIHR Blood and Transplant Research Unit in Donor Health and Behaviour (NIHR203337) (formerly Donor Health and Genomics; NIHR BTRU-2014–10024) and NHS Blood & Transplant (17-01-GEN). The academic coordinating centre at the Department of Public Health and Primary Ca... | PMC10413586 |
Availability of data and materials {29} | Data access requests should be sent to donorhealth@medschl.cam.ac.uk | PMC10413586 | ||
Declarations | PMC10413586 | |||
Ethics approval and consent to participate {24} | This study was approved by Cambridge South Research Ethics Committee (REC reference: 18/EE/0284). | PMC10413586 | ||
Consent for publication {32} | Participants provided consent for the publication of anonymous summary data. | PMC10413586 | ||
Competing interests {28} | J.D. serves on scientific advisory boards for AstraZeneca, Novartis, and UK Biobank, and has received multiple grants from academic, charitable and industry sources outside of the submitted work. M.S. is a full-time employee of AstraZeneca. | PMC10413586 | ||
References | PMC10413586 | |||
Background | neurotoxicity, gastro-esophageal adenocarcinoma | Paclitaxel in combination with ramucirumab is the standard of care second-line therapy in gastro-esophageal adenocarcinoma (GEA). As the number of taxane pretreated patients in the perioperative or first-line setting is increasing, it is unknown whether these patients benefit from re-applying a taxane in using the comb... | PMC10278289 | |
Methods | The RAMIRIS trial is a randomized, open-label, multicenter phase II/III study comparing treatment of FOLFIRI-Ram (arm A) with paclitaxel and ramucirumab (arm B). The Phase II is already closed with 111 enrolled patients. In the phase III, 318 taxane-pretreated patients with advanced GEA will be recruited and randomized... | PMC10278289 | ||
Discussion | toxicity | The already completed RAMIRIS phase II demonstrated feasibility and efficacy of FOLFIRI-Ram. Especially docetaxel-pretreated patients seemed to markedly benefit from FOLFIRI-Ram, with favorable response- and PFS rates and lower toxicity. This offers a rationale for the phase III trial. If the RAMIRIS III trial transfer... | PMC10278289 | |
Trial registration | NCT03081143 | NCT03081143 Date of registration: 13.11.2015 | PMC10278289 | |
Keywords | Open Access funding enabled and organized by Projekt DEAL. | PMC10278289 | ||
Background | colorectal cancer, toxicity, cancer, cancer death, adenocarcinoma, deaths | CANCER, COLORECTAL CANCER, ADENOCARCINOMA, DISEASE PROGRESSION | Gastro-esophageal adenocarcinoma (GEA) is the fifth most common cancer worldwide, causing over one million new cases (1,033,701) each year and is the third-leading cause of cancer death (about 782,685 deaths and 8.2% of total in 2018) [At initial diagnosis more than two thirds of patients are not suitable for curative ... | PMC10278289 |
Study rationale | NCT03081143, neurotoxic | RECURRENCE | Current treatment algorithms recommend a taxane- containing triplet regimen for selected patients as first-line therapy for advanced GEA [Recurrence rates for initially curative treated patients remain high, ranging between 36% to about 70% for patients who received a taxane containing perioperative regimen [As a signi... | PMC10278289 |
Methods / Design | ADVERSE EVENTS, DISEASE | The RAMIRIS trial is a randomized, open-label, multicenter phase II/III study comparing treatment of FOLFIRI-Ram (arm A) with paclitaxel and ramucirumab (arm B) in patients with GEA after prior taxane containing therapy. The study will evaluate the safety and efficacy of the treatment regimens including quality of life... | PMC10278289 | |
Participants | therapyCapability, gastric adenocarcinoma | DISEASE PROGRESSION, RECURRENCE, LIVER METASTASES, ONCOLOGY, GASTRIC ADENOCARCINOMA | Eligible patients need to fulfill all of the following criteria:
Signed written informed consentWomen or men ≥ 18 years of age; Patients in reproductive age must be willing to use adequate contraception during the study and for 3 months after the end of ramucirumab treatment. Women of childbearing age need to have a ne... | PMC10278289 |
Study treatments | PMC10278289 | |||
Arm A - Experimental Treatment consists of: |
Ramucirumab 8 mg/kg intravenously on day 1, 15; q28FOLFIRI (intravenously: Irinotecan 180 mg/m | PMC10278289 | ||
Arm B - Standard Treatment consists of: |
Ramucirumab 8 mg/kg intravenously on day 1, 15; q28Paclitaxel 80 mg/mEach cycle will be repeated after 28 days (from day 1) for a maximum of 1 year. | PMC10278289 | ||
Assessment | tumor, Tumor | DISEASE PROGRESSION, TUMOR, METASTASES, TUMOR | Tumor assessment for study inclusion will be performed within 4 weeks prior to the first dose of study therapy and every eight weeks while treatment. The assessment will be performed by CT scan or MRI from chest to pelvis and all other sites of metastases and should continue until progression. Patients who discontinue ... | PMC10278289 |
Follow up | Tumor | DISEASE PROGRESSION, TUMOR | After discontinuation of study medication patients will be followed up for at least 1 year, every 2 months (except for the first follow up visit, which will be after 30 days due to safety reasons). Tumor assessments per CT scan or MRI will be performed every 8 weeks or until disease progression according to clinical ro... | PMC10278289 |
Statistical methods and data analysis | toxicity, death | EVENT, REMISSION, SOLID TUMORS | The intention of the RAMIRIS Phase III trial is to show a superior therapeutic efficacy of the experimental regimen FOLFIRI-Ram compared to the combination of paclitaxel and ramucirumab in patients pretreated with a taxane. Accordingly, the research hypothesis of the study is one-sided. The primary endpoints are OS and... | PMC10278289 |
Sample size estimation | Looking at results of the RadPAC Trial [On the other hand, only 298 patients are aquired to ensure 80% power to detect an improvement from 10 to 25% for the co-primary endpoint ORR based on an one-sided α error of 0.005. Therefore, 318 patients will be randomized. | PMC10278289 | ||
Discussion | taxane-treated, neutropenia, fatigue, diarrhea, neurotoxicity | CPS, NEUTROPENIA | A high number of first-line taxane-treated patients with GEA relapse and require a second-line treatment. However, data is scarce, whether they benefit more from a re-exposure to a taxane-containing therapy, such as the standard regimen paclitaxel and ramucirumab, than from a taxane-free regimen. Therefore, the Phase I... | PMC10278289 |
Acknowledgements | We thank the patients and their families, the team at Lilly, namely Dr. Christian Schneider-Fresenius, the trial coordination team at the IKF, namely Dr. Claudia Pauligk and all the sites and study teams participating in the trial | PMC10278289 | ||
Authors’ contributions | SL, CP, EG, GS, JRK, GI, TD, MM, JCM, DP, TOG, AS and SEA designed the clinical trial, developed the protocol and recruited patients. The statistics are done by MS. SL and AS wrote the manuscript. SL, CP, EG, GS, JRK, GI, TD, MM, JCM, DP, MS, TOG and SEA contributed to the development and finally approved the manuscrip... | PMC10278289 | ||
Funding | Open Access funding enabled and organized by Projekt DEAL. The legal sponsor of the trial is the Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest (Steinbacher Hohl 2–26, 60488 Frankfurt am Main, Germany). The trial is supported by a research grant for conduction of the clinical trial and supply of... | PMC10278289 | ||
Availability of data and materials | Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest, Steinbacher Hohl 2–26, 60,488 Frankfurt am Main, Germany, | PMC10278289 | ||
Declarations | PMC10278289 | |||
Ethics approval and consent to participate | ICH | ADVERSE EVENTS | This study is conducted in agreement with either the Declaration of Helsinki (in its current version) or the laws and regulations in its current version. The protocol was written, and the study will be conducted according to the ICH Harmonized Tripartite Guideline for Good Clinical Practice. The protocol is approved by... | PMC10278289 |
Consent for publication | Not applicable | PMC10278289 | ||
Competing interests | MM | SL received institutional research grants from Bristol-Myers Squibb and Lilly and serves as an advisory board member for Merck, Bristol-Myers Squibb, Merck Sharp and Dohme, Servier, Sanofi and Amgen. MS is an advisory board member for Bristol-Myers Squibb, Lilly, MSD and is a speaker for Bristol-Myers Squibb, Lilly, MS... | PMC10278289 | |
References | PMC10278289 | |||
Abstract | PMC10632612 | |||
Background | hepatitis C | VIRUS, HEPATITIS C | People who use drugs (PWUD) frequently delay or avoid obtaining medical care in traditional healthcare settings. Through a randomized controlled trial, we investigated facilitated telemedicine for hepatitis C virus (HCV) integrated into opioid treatment programmes. We sought to understand the experiences and meanings o... | PMC10632612 |
Methods | We utilized purposive sampling to interview 25 participants, 6–40 months after achieving an HCV cure. We interpreted and explicated common meanings of participants' experiences of an HCV cure obtained through facilitated telemedicine. | PMC10632612 | ||
Results | DISORDER, INFECTIOUS DISEASE | Participants embraced facilitated telemedicine integrated into opioid treatment programmes as patient‐centred care delivered in ‘safe spaces’ (Theme 1). Participants elucidated their experiences of substance use and HCV while committing to treatment for both entities. Facilitated telemedicine integrated into opioid tre... | PMC10632612 | |
Conclusions | Integrating facilitated telemedicine into opioid treatment programmes addresses several healthcare barriers for PWUD. Similarly, obtaining an HCV cure increases their self‐confidence, permissive to positive lifestyle changes and mitigating the negative consequences of substance use. | PMC10632612 | ||
Patient and Public Contribution | In this study of patient involvement, we interviewed patient‐participants to understand the meaning of an HCV cure through facilitated telemedicine. Participants from a facilitated telemedicine pilot study provided essential input on the design and outcomes of a randomized controlled trial. Pilot study participants end... | PMC10632612 | ||
INTRODUCTION | opioid use disorder, HCV disease, HCV) infection | INFECTIOUS DISEASES, VIRUS, HEPATITIS C | People with opioid use disorder frequently experience related infectious diseases, such as hepatitis C virus (HCV) infection. Because of the opioid epidemic, HCV disease burden is the highest amongst the population that uses injection drugs.Previous literature has described people with opioid use disorder considering o... | PMC10632612 |
METHODS | PMC10632612 | |||
Setting and design | We had an opportunity to interview study participants from a recently completed randomized controlled trial to assess HCV treatment through facilitated telemedicine (intervention) integrated into 12 OTPs throughout New York State compared to usual care, offsite referral to a liver specialist (control condition). | PMC10632612 | ||
Patient and public contribution | LIVER, ABUSE, RECRUITMENT, CHRONIC LIVER DISEASE | This investigation is a study of patient involvement in which patient‐ participants were interviewed to understand the meaning of an HCV cure. Before the randomized controlled trial, we conducted a pilot study to evaluate the acceptability and feasibility of facilitated telemedicine integrated into OTPs for HCV treatme... | PMC10632612 | |
Participant recruitment | We used purposive sampling, consistent with hermeneutic phenomenology study design. | PMC10632612 | ||
Interview conduct | During the interviews, we inquired about participants' experiences of HCV treatment through facilitated telemedicine in OTPs. We used open‐ended questions and interview prompts to facilitate discussion and elaboration. We asked participants to cite specific examples of the care they received, including what was helpful... | PMC10632612 | ||
Qualitative analysis | liver diseases, hepatitis C | VIRUS, LIVER DISEASES, HEPATITIS C | We used hermeneutic phenomenology to understand human situations as they were experienced within a context of time, place, and situational influences, such as obtaining an HCV cure through telemedicine integrated into an OTP.Interpretation of themes was revealed through experiences, as captured through the participant ... | PMC10632612 |
RESULTS | DISORDER, DISORDER | Our interpretation includes four themes and one constitutive pattern to explicate ‘Facilitated Telemedicine for HCV: Addressing Challenges for Improving Health and Life for People with Opioid Use Disorder’. Themes illustrate patients' experiences of (1) embracing facilitated telemedicine in the OTP; (2) committing to t... | PMC10632612 | |
Theme 1: Embracing facilitated telemedicine in the OTP | hepatitis | DISORDER, VIRUS, HEPATITIS C, LITTLE, HEPATITIS | Participants viewed their OTPs as supportive and trusting environments, qualities that extended to the telemedicine encounter and provider. Overall, participants were enthusiastic about healthcare delivery through facilitated telemedicine. One participant explained that onsite facilitated telemedicine for healthcare de... | PMC10632612 |
Theme 2: Committing to the OTP and HCV treatment | depression, vulgar’, anxiety | DISORDER | Participants described their experiences of substance use as losing control of their lives. One participant described his substance use as a primary need ‘to feel a high. [You] will spend all your money, [and] the next day, you're broke’. When experiencing substance use disorder, participants also struggle with symptom... | PMC10632612 |
Theme 3: Facing negative perceptions of HCV and substance use disorder | Participants referred to themselves as ‘addicts’, a learned label and attitude associated with substance use that reinforces negative self‐perceptions. This attitude was revealed in the language that participants used to refer to themselves as ‘dirty’ or ‘clean’ depending on their current state of substance use, as one... | PMC10632612 | ||
Subtheme 3a: Confronting poor relations with external healthcare providers | prejudice, pain | Participants revealed that one of the advantages of facilitated telemedicine situated in the OTP is that it permits them to circumvent the obstacles they face in traditional healthcare settings where they are ‘labelled as a drug user’. One participant related a similar sentiment when seeking healthcare in a conventiona... | PMC10632612 | |
Subtheme 3b: Enduring negative perceptions of substance use disorder in society | opioid use disorder, drug abuse, drug addiction, Drug [addiction | DISORDER, DISEASE | Participants related experiences in society where they were judged for their substance use disorder as a moral failing, a misunderstanding of the basis of substance use disorder as a physiologic medical condition, as one participant summarized:A lot of people have no education about drugs, all they know is from movies…... | PMC10632612 |
Subtheme 3c: HCV diagnosis as shameful | opioid addiction | DISORDER | As participants progress through treatment for opioid addiction, they develop self‐awareness of the misunderstandings of substance use disorder, associated comorbid conditions such as HCV, and of the negative attitudes held by people outside of the OTP. ‘They think that because you're on methadone, you're sh**, you're ... | PMC10632612 |
Theme 4: Engaging in HCV treatment to improve health | headaches, anxiety, shakes, HCV infection, pain, hepatitis C, sweats, hepatitis | DISEASE, HEPATITIS C, HEPATITIS | Several participants were motivated to pursue HCV treatment because they viewed HCV infection as a lethal disease, and they personally knew friends and family who died of HCV:I don't want to pass hepatitis C to nobody… I know that hepatitis C is hard. I got family, my niece passed away [from] hepatitis C… I [want] to g... | PMC10632612 |
Constitutive pattern | PMC10632612 | |||
Facilitated telemedicine for HCV: Addressing challenges for improving health and life for people with opioid use disorder | addict”’.‘If, go”’.‘Confidentiality, pain, hepatitis C, drug abuse, hepatitis | HEPATITIS C, VIRUS, SAID, HEPATITIS | Participants underscore the convenience and confidentiality of facilitated telemedicine integrated into the OTP, providing access to patient‐centred care, and circumventing external providers. They embrace facilitated telemedicine as promoting a therapeutic relationship between patients and telemedicine providers. Thes... | PMC10632612 |
DISCUSSION | hepatitis C, HCV infection, anxiety | DISORDER, VIRUS, DISEASE, HEPATITIS C, SEPARATION, HEPATITIS C | Participants revealed how facilitated telemedicine expanded healthcare access in the OTP, which they consider a ‘safe space’ that is supportive, trusting, and destigmatizing. Similarly, other research described OTPs as accepting and comfortable environments.Although substance use disorder is a physiologic medical condi... | PMC10632612 |
CONCLUSIONS | DISORDER | Participants' stories described how the trusted environment of the OTP promotes substance use disorder treatment. Facilitated telemedicine, along with the integrated case manager and interdisciplinary team of OTP staff, provide patient‐centred care for HCV, while simultaneously addressing participants' concerns. The cu... | PMC10632612 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.